Nature Reviews Drug Discovery (2020) https://doi.org/10.1038/s41573-019-0056-x Published online 14 February 2020
In the subsection on post-licensure considerations, the authors wish to clarify that accelerated licensure granted for high-dose trivalent influenza vaccine was independent of the 2009 H1N1 outbreak, and the randomized controlled trial in approximately 31,000 adults 65 years of age and older showed that the high-dose influenza vaccine demonstrated clear superior efficacy relative to the standard-dose vaccine210. Text in this subsection has been modified accordingly.
About this article
Cite this article
Wei, C., Crank, M.C., Shiver, J. et al. Author Correction: Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov (2020). https://doi.org/10.1038/s41573-020-0066-8